LONDON (Alliance News) - C4X Discovery Holdings PLC said Monday that has entered into a research agreement with Evotec AG with the collaborate on developing a series of orexin-1 selective inhibitors.
The company said that under the agreement it will combine its technology and design expertise with Evotec's biology and chemistry expertise. C4XD has a technology that can generate 3D structures of drug molecules that helps to accelerate product development, it said.
The company said that activation of the orexin-1 receptor in the brain is associated with stress related addictive disorders, whilst the activation of orexin-2 receptor is associated with biorythms and wakefulness. It said that identifying compounds that inhibit the orexin-1 pathway should therefore provide treatments for addiction whilst avoiding the sedative effects associated with inhibition of orexin-2.
Shares in C4X are untraded Monday. It last closed at 87.00 pence.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
